BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21750532)

  • 1. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
    Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
    Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
    Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
    Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.
    Huston MW; Riegman AR; Yadak R; van Helsdingen Y; de Boer H; van Til NP; Wagemaker G
    Hum Gene Ther; 2014 Oct; 25(10):905-14. PubMed ID: 25222508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
    Mamcarz E; Zhou S; Lockey T; Abdelsamed H; Cross SJ; Kang G; Ma Z; Condori J; Dowdy J; Triplett B; Li C; Maron G; Aldave Becerra JC; Church JA; Dokmeci E; Love JT; da Matta Ain AC; van der Watt H; Tang X; Janssen W; Ryu BY; De Ravin SS; Weiss MJ; Youngblood B; Long-Boyle JR; Gottschalk S; Meagher MM; Malech HL; Puck JM; Cowan MJ; Sorrentino BP
    N Engl J Med; 2019 Apr; 380(16):1525-1534. PubMed ID: 30995372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.
    van Til NP; de Boer H; Mashamba N; Wabik A; Huston M; Visser TP; Fontana E; Poliani PL; Cassani B; Zhang F; Thrasher AJ; Villa A; Wagemaker G
    Mol Ther; 2012 Oct; 20(10):1968-80. PubMed ID: 22692499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome.
    van Til NP; Sarwari R; Visser TP; Hauer J; Lagresle-Peyrou C; van der Velden G; Malshetty V; Cortes P; Jollet A; Danos O; Cassani B; Zhang F; Thrasher AJ; Fontana E; Poliani PL; Cavazzana M; Verstegen MM; Villa A; Wagemaker G
    J Allergy Clin Immunol; 2014 Apr; 133(4):1116-23. PubMed ID: 24332219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
    Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
    Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency.
    Poletti V; Charrier S; Corre G; Gjata B; Vignaud A; Zhang F; Rothe M; Schambach A; Gaspar HB; Thrasher AJ; Mavilio F
    Mol Ther Methods Clin Dev; 2018 Jun; 9():257-269. PubMed ID: 29707600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.
    De Ravin SS; Wu X; Moir S; Anaya-O'Brien S; Kwatemaa N; Littel P; Theobald N; Choi U; Su L; Marquesen M; Hilligoss D; Lee J; Buckner CM; Zarember KA; O'Connor G; McVicar D; Kuhns D; Throm RE; Zhou S; Notarangelo LD; Hanson IC; Cowan MJ; Kang E; Hadigan C; Meagher M; Gray JT; Sorrentino BP; Malech HL; Kardava L
    Sci Transl Med; 2016 Apr; 8(335):335ra57. PubMed ID: 27099176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.
    Punwani D; Kawahara M; Yu J; Sanford U; Roy S; Patel K; Carbonaro DA; Karlen AD; Khan S; Cornetta K; Rothe M; Schambach A; Kohn DB; Malech HL; McIvor RS; Puck JM; Cowan MJ
    Hum Gene Ther; 2017 Jan; 28(1):112-124. PubMed ID: 27611239
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Rajawat YS; Humbert O; Cook SM; Radtke S; Pande D; Enstrom M; Wohlfahrt ME; Kiem HP
    Hum Gene Ther; 2021 Jan; 32(1-2):113-127. PubMed ID: 32741228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer.
    Pike-Overzet K; Rodijk M; Ng YY; Baert MR; Lagresle-Peyrou C; Schambach A; Zhang F; Hoeben RC; Hacein-Bey-Abina S; Lankester AC; Bredius RG; Driessen GJ; Thrasher AJ; Baum C; Cavazzana-Calvo M; van Dongen JJ; Staal FJ
    Leukemia; 2011 Sep; 25(9):1471-83. PubMed ID: 21617701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for PIDs: progress, pitfalls and prospects.
    Mukherjee S; Thrasher AJ
    Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.
    Throm RE; Ouma AA; Zhou S; Chandrasekaran A; Lockey T; Greene M; De Ravin SS; Moayeri M; Malech HL; Sorrentino BP; Gray JT
    Blood; 2009 May; 113(21):5104-10. PubMed ID: 19286997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell differentiation and IL-21 response in
    Miggelbrink AM; Logan BR; Buckley RH; Parrott RE; Dvorak CC; Kapoor N; Abdel-Azim H; Prockop SE; Shyr D; Decaluwe H; Hanson IC; Gillio A; Dávila Saldaña BJ; Eibel H; Hopkins G; Walter JE; Whangbo JS; Kohn DB; Puck JM; Cowan MJ; Griffith LM; Haddad E; O'Reilly RJ; Notarangelo LD; Pai SY
    Blood; 2018 Jun; 131(26):2967-2977. PubMed ID: 29728406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
    Hiramoto T; Li LB; Funk SE; Hirata RK; Russell DW
    Mol Ther; 2018 May; 26(5):1255-1265. PubMed ID: 29606506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.
    van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Hacein-Bey-Abina S; Nordling DL; Cavazzana-Calvo M; Thrasher AJ; Williams DA; Reeves L; Malik P
    Gene Ther; 2012 Aug; 19(8):872-6. PubMed ID: 22551777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of transgene regulation in ex vivo lentiviral correction of artemis deficiency.
    Multhaup MM; Podetz-Pedersen KM; Karlen AD; Olson ER; Gunther R; Somia NV; Blazar BR; Cowan MJ; McIvor RS
    Hum Gene Ther; 2015 Apr; 26(4):232-43. PubMed ID: 25738323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of SCID-X1 using an enhancerless Vav promoter.
    Almarza E; Zhang F; Santilli G; Blundell MP; Howe SJ; Thornhill SI; Bueren JA; Thrasher AJ
    Hum Gene Ther; 2011 Mar; 22(3):263-70. PubMed ID: 20887212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.